Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI)
- PMID: 18043911
- DOI: 10.1007/s00228-007-0404-3
Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI)
Abstract
Objective: To investigate the influence of paroxetine on metoprolol concentrations and its effect in patients treated for acute myocardial infarction (AMI) who are routinely given paroxetine as a co-treatment of depression.
Methods: We recruited 17 depressed AMI patients who received metoprolol as a routine part of their therapy (mean dose 75 +/- 39 mg/day). Patients were genotyped for CYP2D6 3, 4 and gene duplication. Metoprolol and alpha-hydroxy-metoprolol were analyzed in plasma 0, 2, 6 and 12 h post-dose. Heart rates (HR) at rest were registered after each sampling. Paroxetine 20 mg daily was then administered, and all measurements were repeated on day 8.
Results: All patients were genotypically extensive metabolizers (EMs) (nine with 1/1 and eight with 1/3 or 4). Following the administration of paroxetine, mean metoprolol areas under the concentration-time curve (AUC) increased (1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 +/- 1.3 to 26 +/- 29; P < 0.0001). Mean HRs were significantly lower after the study week at each time point. Mean area under the HR versus time curve (AUEC) decreased (835 +/- 88 to 728 +/- 84 beats x h/min; P = 0.0007). Metoprolol AUCs correlated with patients' AUECs at the baseline (Spearman r = -0.64, P < 0.01), but not on the eighth day of the study. A reduction of metoprolol dose was required in two patients due to excessive bradycardia and severe orthostatic hypotension. No other adverse effects of the drugs were identified.
Conclusion: A pronounced inhibition of metoprolol metabolism by paroxetine was observed in AMI patients, but without serious adverse effects. We suggest, however, that the metoprolol dose is controlled upon initiation and withdrawal of paroxetine.
Similar articles
-
CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction.Eur J Clin Pharmacol. 2008 Dec;64(12):1163-73. doi: 10.1007/s00228-008-0525-3. Epub 2008 Jul 22. Eur J Clin Pharmacol. 2008. PMID: 18648788 Clinical Trial.
-
Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.Fundam Clin Pharmacol. 2004 Feb;18(1):113-23. doi: 10.1046/j.1472-8206.2003.00216.x. Fundam Clin Pharmacol. 2004. PMID: 14748763 Clinical Trial.
-
Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.Clin Pharmacol Ther. 2000 Mar;67(3):283-91. doi: 10.1067/mcp.2000.104788. Clin Pharmacol Ther. 2000. PMID: 10741632 Clinical Trial.
-
The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine.Br J Clin Pharmacol. 2018 Dec;84(12):2704-2715. doi: 10.1111/bcp.13741. Epub 2018 Sep 24. Br J Clin Pharmacol. 2018. PMID: 30248178 Free PMC article.
-
[Interactions between metoprolol and antidepressants].Tidsskr Nor Laegeforen. 2011 Sep 20;131(18):1777-9. doi: 10.4045/tidsskr.11.0143. Tidsskr Nor Laegeforen. 2011. PMID: 21946596 Review. Norwegian.
Cited by
-
Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly.Pharmacoepidemiol Drug Saf. 2018 Jun;27(6):621-629. doi: 10.1002/pds.4422. Epub 2018 Mar 24. Pharmacoepidemiol Drug Saf. 2018. PMID: 29575226 Free PMC article.
-
Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine.J Clin Pharmacol. 2011 Mar;51(3):389-96. doi: 10.1177/0091270010365559. Epub 2010 Apr 16. J Clin Pharmacol. 2011. PMID: 20400652 Free PMC article. Clinical Trial.
-
Impact of the CYP2D6 Genotype on Metoprolol Tolerance and Adverse Events in Elderly Chinese Patients With Cardiovascular Diseases.Front Pharmacol. 2022 Apr 6;13:876392. doi: 10.3389/fphar.2022.876392. eCollection 2022. Front Pharmacol. 2022. PMID: 35462926 Free PMC article.
-
Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.Eur J Clin Pharmacol. 2022 Oct;78(10):1623-1632. doi: 10.1007/s00228-022-03364-5. Epub 2022 Jul 25. Eur J Clin Pharmacol. 2022. PMID: 35871665 Free PMC article.
-
Is antiarrhythmic treatment in the elderly different? a review of the specific changes.Drugs Aging. 2011 Aug 1;28(8):617-33. doi: 10.2165/11591680-000000000-00000. Drugs Aging. 2011. PMID: 21812498 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical